Which has preferable earnings & valuation, ARGX or GMAB?

argenex has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 13.76 $1.29B $22.46 41.84 Genmab A/S $3.72B 4.78 $963M $1.32 21.60

Is ARGX or GMAB more profitable?

argenex has a net margin of 31.31% compared to Genmab A/S's net margin of 21.05%. argenex's return on equity of 44.37% beat Genmab A/S's return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 44.37% 37.55% Genmab A/S 21.05% 15.34% 8.94%

Does the media refer more to ARGX or GMAB?

In the previous week, Genmab A/S had 2 more articles in the media than argenex. MarketBeat recorded 5 mentions for Genmab A/S and 3 mentions for argenex. Genmab A/S's average media sentiment score of 0.69 beat argenex's score of 0.33 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer GMAB or TAK?

Genmab A/S currently has a consensus price target of $38.21, indicating a potential upside of 34.04%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts plainly believe Genmab A/S is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.75 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media favor GMAB or TAK?

In the previous week, Genmab A/S and Genmab A/S both had 5 articles in the media. Genmab A/S's average media sentiment score of 0.69 beat Takeda Pharmaceutical's score of 0.15 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GMAB or RVMD?

In the previous week, Revolution Medicines had 9 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Revolution Medicines and 5 mentions for Genmab A/S. Revolution Medicines' average media sentiment score of 0.73 beat Genmab A/S's score of 0.69 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor GMAB or TEVA?

In the previous week, Teva Pharmaceutical Industries had 1 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Teva Pharmaceutical Industries and 5 mentions for Genmab A/S. Teva Pharmaceutical Industries' average media sentiment score of 1.47 beat Genmab A/S's score of 0.69 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ONC or GMAB more profitable?

Genmab A/S has a net margin of 21.05% compared to BeOne Medicines' net margin of 8.94%. Genmab A/S's return on equity of 15.34% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 8.94% 12.06% 6.69% Genmab A/S 21.05% 15.34% 8.94%

Does the media refer more to ONC or GMAB?

In the previous week, Genmab A/S had 1 more articles in the media than BeOne Medicines. MarketBeat recorded 5 mentions for Genmab A/S and 4 mentions for BeOne Medicines. Genmab A/S's average media sentiment score of 0.69 beat BeOne Medicines' score of 0.35 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Genmab A/S (GMAB) Competitors

$28.51 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$28.52 +0.00 (+0.02%)

As of 07/2/2026 05:50 PM Eastern

Compare

GMAB vs. ARGX, TAK, RVMD, TEVA, and ONC

Should you buy Genmab A/S stock or one of its competitors? MarketBeat compares Genmab A/S with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genmab A/S include argenex (ARGX), Takeda Pharmaceutical (TAK), Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), and BeOne Medicines (ONC). These companies are all part of the "pharmaceutical products" industry.

How does Genmab A/S compare to argenex?

argenex (NASDAQ:ARGX) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

In the previous week, Genmab A/S had 2 more articles in the media than argenex. MarketBeat recorded 5 mentions for Genmab A/S and 3 mentions for argenex. Genmab A/S's average media sentiment score of 0.69 beat argenex's score of 0.33 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex currently has a consensus price target of $1,034.56, suggesting a potential upside of 10.10%. Genmab A/S has a consensus price target of $38.21, suggesting a potential upside of 34.04%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

argenex has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	13.76	$1.29B	$22.46	41.84
Genmab A/S	$3.72B	4.78	$963M	$1.32	21.60

argenex has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

60.3% of argenex shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 2.4% of argenex shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

argenex has a net margin of 31.31% compared to Genmab A/S's net margin of 21.05%. argenex's return on equity of 44.37% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
Genmab A/S	21.05%	15.34%	8.94%

Summary

argenex beats Genmab A/S on 13 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to Takeda Pharmaceutical?

Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

Genmab A/S has a net margin of 21.05% compared to Takeda Pharmaceutical's net margin of 4.31%. Genmab A/S's return on equity of 15.34% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Takeda Pharmaceutical	4.31%	11.20%	5.48%

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Genmab A/S and Genmab A/S both had 5 articles in the media. Genmab A/S's average media sentiment score of 0.69 beat Takeda Pharmaceutical's score of 0.15 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market.

Genmab A/S has higher earnings, but lower revenue than Takeda Pharmaceutical. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.78	$963M	$1.32	21.60
Takeda Pharmaceutical	$28.32B	1.88	-$1.01B	$0.39	42.91

Genmab A/S currently has a consensus price target of $38.21, indicating a potential upside of 34.04%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts plainly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Genmab A/S beats Takeda Pharmaceutical on 13 of the 16 factors compared between the two stocks.

How does Genmab A/S compare to Revolution Medicines?

Genmab A/S (NASDAQ:GMAB) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Genmab A/S has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

Genmab A/S has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.78	$963M	$1.32	21.60
Revolution Medicines	$11.58M	3,474.30	-$1.13B	-$7.07	N/A

Genmab A/S presently has a consensus target price of $38.21, suggesting a potential upside of 34.04%. Revolution Medicines has a consensus target price of $135.39, suggesting a potential downside of 28.46%. Given Genmab A/S's higher possible upside, analysts clearly believe Genmab A/S is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00

Genmab A/S has a net margin of 21.05% compared to Revolution Medicines' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Revolution Medicines	N/A	-83.22%	-59.06%

In the previous week, Revolution Medicines had 9 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Revolution Medicines and 5 mentions for Genmab A/S. Revolution Medicines' average media sentiment score of 0.73 beat Genmab A/S's score of 0.69 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Revolution Medicines beats Genmab A/S on 9 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to Teva Pharmaceutical Industries?

Genmab A/S (NASDAQ:GMAB) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Teva Pharmaceutical Industries has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.78	$963M	$1.32	21.60
Teva Pharmaceutical Industries	$17.26B	2.30	$1.41B	$1.33	25.98

Genmab A/S has a net margin of 21.05% compared to Teva Pharmaceutical Industries' net margin of 9.01%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

In the previous week, Teva Pharmaceutical Industries had 1 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Teva Pharmaceutical Industries and 5 mentions for Genmab A/S. Teva Pharmaceutical Industries' average media sentiment score of 1.47 beat Genmab A/S's score of 0.69 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S currently has a consensus price target of $38.21, indicating a potential upside of 34.04%. Teva Pharmaceutical Industries has a consensus price target of $41.78, indicating a potential upside of 20.91%. Given Genmab A/S's higher possible upside, equities research analysts clearly believe Genmab A/S is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Genmab A/S has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Teva Pharmaceutical Industries beats Genmab A/S on 11 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

Genmab A/S has lower revenue, but higher earnings than BeOne Medicines. Genmab A/S is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.11	$286.93M	$4.47	66.59
Genmab A/S	$3.72B	4.78	$963M	$1.32	21.60

Genmab A/S has a net margin of 21.05% compared to BeOne Medicines' net margin of 8.94%. Genmab A/S's return on equity of 15.34% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Genmab A/S	21.05%	15.34%	8.94%

BeOne Medicines presently has a consensus price target of $390.00, suggesting a potential upside of 31.03%. Genmab A/S has a consensus price target of $38.21, suggesting a potential upside of 34.04%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Genmab A/S had 1 more articles in the media than BeOne Medicines. MarketBeat recorded 5 mentions for Genmab A/S and 4 mentions for BeOne Medicines. Genmab A/S's average media sentiment score of 0.69 beat BeOne Medicines' score of 0.35 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

BeOne Medicines beats Genmab A/S on 9 of the 17 factors compared between the two stocks.

Get Genmab A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMAB vs. The Competition

Export

Metric	Genmab A/S	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$17.78B	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.67%	6.51%
P/E Ratio	21.60	21.61	28.02	24.70
Price / Sales	4.78	325.99	534.82	99.69
Price / Cash	17.72	147.12	49.26	57.09
Price / Book	3.13	8.66	10.96	6.46
Net Income	$963M	$23.81M	$3.57B	$337.01M
7 Day Performance	9.21%	3.39%	2.12%	1.69%
1 Month Performance	13.36%	10.81%	5.25%	3.81%
1 Year Performance	39.69%	62.61%	33.29%	23.90%

Genmab A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMAB Genmab A/S	4.7856 of 5 stars	$28.51 flat	$38.21 +34.0%	+39.7%	$17.78B	$3.72B	21.60	3,029	Analyst Forecast
ARGX argenex	3.67 of 5 stars	$912.46 +2.8%	$1,023.39 +12.2%	+73.0%	$55.17B	$4.25B	40.63	1,863	Analyst Forecast
TAK Takeda Pharmaceutical	2.0519 of 5 stars	$15.97 +0.3%	N/A	+7.6%	$50.63B	$28.32B	40.94	47,455	Gap Down
RVMD Revolution Medicines	1.8894 of 5 stars	$192.62 +5.8%	$132.78 -31.1%	+411.5%	$38.71B	$11.58M	N/A	250	News Coverage Analyst Forecast Insider Trade
TEVA Teva Pharmaceutical Industries	4.7447 of 5 stars	$33.20 0.0%	$41.78 +25.8%	+102.7%	$38.19B	$17.26B	24.96	33,950	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GMAB) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genmab A/S (GMAB) Competitors

GMAB vs. ARGX, TAK, RVMD, TEVA, and ONC

How does Genmab A/S compare to argenex?

Summary

How does Genmab A/S compare to Takeda Pharmaceutical?

Summary

How does Genmab A/S compare to Revolution Medicines?

Summary

How does Genmab A/S compare to Teva Pharmaceutical Industries?

Summary

How does Genmab A/S compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMAB vs. The Competition

Genmab A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genmab A/S (GMAB) Competitors

GMAB vs. ARGX, TAK, RVMD, TEVA, and ONC

How does Genmab A/S compare to argenex?

Does the media refer more to ARGX or GMAB?

Do analysts recommend ARGX or GMAB?

Which has preferable earnings & valuation, ARGX or GMAB?

Which has more volatility & risk, ARGX or GMAB?

Do institutionals & insiders hold more shares of ARGX or GMAB?

Is ARGX or GMAB more profitable?

Summary

How does Genmab A/S compare to Takeda Pharmaceutical?

Is GMAB or TAK more profitable?

Do institutionals and insiders believe in GMAB or TAK?

Does the media favor GMAB or TAK?

Which has more risk and volatility, GMAB or TAK?

Which has higher valuation & earnings, GMAB or TAK?

Do analysts prefer GMAB or TAK?

Summary

How does Genmab A/S compare to Revolution Medicines?

Do institutionals and insiders hold more shares of GMAB or RVMD?

Which has more volatility & risk, GMAB or RVMD?

Which has higher valuation and earnings, GMAB or RVMD?

Do analysts prefer GMAB or RVMD?

Is GMAB or RVMD more profitable?

Does the media prefer GMAB or RVMD?

Summary

How does Genmab A/S compare to Teva Pharmaceutical Industries?

Which has better valuation & earnings, GMAB or TEVA?

Is GMAB or TEVA more profitable?

Does the media favor GMAB or TEVA?

Do analysts recommend GMAB or TEVA?

Which has more volatility & risk, GMAB or TEVA?

Do institutionals & insiders have more ownership in GMAB or TEVA?

Summary

How does Genmab A/S compare to BeOne Medicines?

Which has more volatility and risk, ONC or GMAB?

Which has higher valuation & earnings, ONC or GMAB?

Is ONC or GMAB more profitable?

Do analysts recommend ONC or GMAB?

Does the media refer more to ONC or GMAB?

Do institutionals and insiders believe in ONC or GMAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMAB vs. The Competition

Genmab A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools